[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].

Objective To evaluate the short-term efficacy and toxicity of endostar in combination with XELIRI as the second-line treatment for advanced colorectal cancer.Methods Twenty-one patients with advanced colorectal cancer were treated with intravenous infusion of endostar (15 mg/day for 14 consecutive days) and irinotecan (250 mg/m2,single dose on the first day),and oral administration of capecitabine (1.0 mg/m2,twice daily for 14 days),and the treatment cycle was repeated every 21 days.The efficacy and toxicity of the treatments were evaluated according to RECIST and NCI-CTCAE3.0 standard,respectively.Results The overall response rate was 9.5% in these patients,with a median time to progression (mTTP) of 3.9 months.The main adverse effects associated with the treatment included leucopenia,nausea/vomiting and peripheral neuritis.Conclusion Endostar combined with XELIRI is effective and safe as the second-line treatment for advanced colorectal cancer,and further clinical investigation is warranted.